Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

- PMLiVE

Compass Therapeutics’ tovecimig shows promise in phase 2/3 biliary tract cancer study

Around 23,000 cases of the aggressive cancer are diagnosed in the US every year

- PMLiVE

BMS granted FDA approval for immunotherapy combination in colorectal cancer

More than 154,000 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis

The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

- PMLiVE

Johnson & Johnson shares positive late-stage results for Tremfya in psoriatic arthritis

The inflammatory condition affects approximately 30% of psoriasis patients

- PMLiVE

Collaboration Across Healthcare is the Path Forward

How do we impress upon women that they need to prioritize their own health before providing for the people who need them? A leader in medical oncology has a few...

Medscape Education

- PMLiVE

Eli Lilly and Sangamo Therapeutics enter CNS disease partnership worth over $1.4bn

The deal gives Lilly access to Sangamo’s neurotropic adeno-associated virus capsid

- PMLiVE

Ipsen’s Iqirvo accepted by SMC to treat rare liver disease primary biliary cholangitis

The life-long condition affects approximately 1,900 people in Scotland

- PMLiVE

Naturally occurring peptide shows promise as potential psoriasis treatment

The approach could reduce disease severity with fewer side effects than conventional treatments

Smart-Works-Leeds-Office

Digital agency, Mednet, supporting women back into work

Mednet, a digital marketing and brand partner in Pharma, has recently strengthened its partnership with women’s charity Smart Works Leeds by donating fully-wiped and refurbished laptops to support the charity’s...

Mednet

- PMLiVE

GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

- PMLiVE

AstraZeneca’s Imfinzi regimen receives EC approval to treat resectable NSCLC

More than 450,000 people are diagnosed with lung cancer every year in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links